Both the novel Bayer patch and the COC showed good contraceptive efficacy in this study, with no pregnancies occurring during either treatment. One pregnancy occurred during the second washout phase of this study; however, this occurred after intake of the last COC tablet. Despite these favorable results, caution should be taken when interpreting these findings with the aim of predicting VTE risk among users of different hormonal contraceptives. Although comparative pharmacodynamic
data may be used to indicate possible differences between products, there are no generally accepted surrogate endpoints. In addition, it should also be noted that the inability of this study to find any differences between GSK872 mouse treatments may be a reflection of its small sample size and relatively short treatment duration. In addition lipid metabolism was not
assessed in the present study. However, study data have shown that low-density lipoprotein cholesterol levels (LDL-C) decrease and triglyceride and high-density lipoprotein cholesterol (HDL-C) levels increase from baseline levels after treatment with a contraceptive preparation that contains gestodene and EE. These changes resulted in an LY2874455 order increased HDL-C/LDL-C ratio, demonstrating that the contraceptive had an anti-atherogenic effect [29]. 5 Conclusion The results of GDC941 this crossover, comparative study demonstrate that both the novel Bayer Inositol oxygenase patch delivering low doses of EE and gestodene and a low-dose, monophasic COC containing EE and levonorgestrel have comparable influence on hemostatic endpoints. Both treatments were well-tolerated by subjects, and no clinically significant laboratory changes were observed. Acknowledgments The study was funded by Bayer Pharma AG. Statistical support was provided by Mr Keith Falconer and Mr Florian Hiemeyer. Editorial assistance was provided by Ogilvy 4D, Oxford, UK, and was funded by Bayer Pharma AG. Professor Junge has no financial involvements to disclose. Dr Heger-Mahn has received research funding
from Bayer Pharma AG. Mr Trummer and Dr Merz are employees of Bayer Pharma AG. Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. References 1. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA. 2004;291(13):1610–20.PubMedCrossRef 2. Janssen–Cilag. Evra transdermal patch. Summary of product characteristics. 2012. http://www.medicines.ie/medicine/2273/SPC/Evra+transdermal+patch/. Accessed 5 Mar 2013. 3. UN Department of Economic and Social Affairs Population Division. World contraceptive use. 2011. http://www.un.